retatrutide triple agonist glp-1 gip glucagon phase 2 results Beyond GLP-1: Retatrutide's triple-agonist mechanism (GLP-1, GIP, glucagon) is redefining metabolic health. data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing Difference between tirzepatide and retatrutide:

Description

The primary endpoint occurred in 569 of 8803 participants (6.5%) in the semaglutide group compared with 701 of 8801 participants (8.0%) in the placebo group, corresponding to an HR of 0.80 (95% CI, 0.720.90

10.3310/hta14360 192 WeirD

Not every insurance plan includes benefits for GLP-1 medications or physician-guided medical weight loss

GM: Writing review and editing

This review critically examines the current evidence supporting the use of GLP-1 RAs, including their efficacy, safety, cost-effectiveness, and ethical implications in the pediatric population